Announcements
- Hyloris Reports Full Year Results for 2023 & Provides Business Outlook
- Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives
- Communication at the request of the FSMA on the transactions with Qliniq
- Communiqué à la requête de la FSMA sur les transactions avec QliniQ
- Hyloris to Report 2023 Full-Year Results on 14 March 2024
- Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024
- Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada
- Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au Canada
- Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures
- Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions Dentaires
More ▼
Key statistics
On Monday, Hyloris Pharmaceuticals SA (52U:DUS) closed at 11.50, 5.50% above its 52-week low of 10.90, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | 11.50 |
Offer | 12.00 |
Previous close | 11.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 28.00m |
Free float | 12.15m |
P/E (TTM) | -- |
Market cap | 327.60m EUR |
EPS (TTM) | -0.5795 EUR |
Data delayed at least 15 minutes, as of Apr 29 2024 07:12 BST.
More ▼